There was no therapeutic improvement when both SMG1 and IL-6 were inhibited concurrently with ICB treatment; suggesting that one of the most relevant mechanisms of action for IL-6 inhibition may be related to controlling NMD activity and further confirming the here revealed cross-talk of these two pathways in determining tumor immunogenicity (Fig. 7L). This evidence concerns the gene IL6 and neoplasm.